Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734851 · ClinicalTrials.gov registry record · Phase 2
Multimodality Phase II Study in Prostate Cancer
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00734851 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 36 participants.
The verdict
NCT00734851, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a single arm phase II study of docetaxel, prednisone, and sunitinib systemic therapy followed by salvage external beam radiation therapy for men who have experienced PSA recurrence following initial radical prostatectomy for prostate cancer. The primary aim is the rate of progression-free survival at 2 years as measured by lack of PSA progression and no evidence of disease. We hypothesize that this aggressive initial systemic therapy will improve the long term remission rates for men who are undergoing salvage radiation therapy for PSA recurrence in the absence of metastatic disease.
Interventions
- DRUG Docetaxel
- DRUG Sunitinib
- RADIATION EBXRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734851
The ClinicalTrials.gov registry entry for NCT00734851 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00734851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00734851 about?
NCT00734851 is a clinical study titled "Multimodality Phase II Study in Prostate Cancer". This is a single arm phase II study of docetaxel, prednisone, and sunitinib systemic therapy followed by salvage external beam radiation therapy for men who have experienced PSA recurrence following initial radical prostatectomy for prostate cancer. The primary aim is the rate of progression-free su...
What is the current status of trial NCT00734851?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2008-12. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00734851?
The interventions under investigation include: Docetaxel (DRUG), Sunitinib (DRUG), EBXRT (RADIATION).
Who is sponsoring clinical trial NCT00734851?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.